FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896681144> ?p ?o ?g. }

• W2896681144 endingPage "31" @default.
• W2896681144 startingPage "22" @default.
• W2896681144 abstract "Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically adjusted normative data and were classified as impaired (defined as either a z-score ≤ - 2 or having 2 or more standardized individual test z-scores ≤ - 1); while higher scores (equaling better performance) were classified as normal. By z-scores, 54.7% of participants had impaired neurocognition at baseline and 50.2% at week 48. There were no significant differences (p < 0.05) in the baseline-adjusted performance between treatment groups for any individual test or by z-score. Specific demographic and medical risk factors were evaluated by univariate analysis for impact on neurocognitive performance. Factors with p < 0.10 were evaluated by backwards regression analysis to identify neurocognition-correlated factors after accounting for treatment, assessment, and baseline. Four risk factors at baseline for impaired neurocognition were initially identified: lower CD4 nadir lymphocyte counts, higher Framingham risk scores, and interleukin-6 levels, and a history of psychiatric disorder not otherwise specified, however none were found to moderate the effect of treatment on neurocognition. In this aviremic, treatment-experienced population, baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks with both TDF/FTC + ATV/r-treated and in the ART-simplified ABC/3TC + ATV treatment groups." @default.
• W2896681144 created "2018-10-26" @default.
• W2896681144 creator A5021428464 @default.
• W2896681144 creator A5055996321 @default.
• W2896681144 creator A5060710888 @default.
• W2896681144 creator A5064879007 @default.
• W2896681144 creator A5069581471 @default.
• W2896681144 creator A5076360870 @default.
• W2896681144 creator A5079973774 @default.
• W2896681144 date "2018-10-08" @default.
• W2896681144 modified "2023-09-26" @default.
• W2896681144 title "Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir" @default.
• W2896681144 cites W1573880500 @default.
• W2896681144 cites W1967448985 @default.
• W2896681144 cites W1980690358 @default.
• W2896681144 cites W1980954820 @default.
• W2896681144 cites W1981473511 @default.
• W2896681144 cites W1986969634 @default.
• W2896681144 cites W1988101744 @default.
• W2896681144 cites W1988633664 @default.
• W2896681144 cites W2016935557 @default.
• W2896681144 cites W2019013083 @default.
• W2896681144 cites W2021309726 @default.
• W2896681144 cites W2022100968 @default.
• W2896681144 cites W2023292268 @default.
• W2896681144 cites W2030502847 @default.
• W2896681144 cites W2050100208 @default.
• W2896681144 cites W2064341017 @default.
• W2896681144 cites W2066816136 @default.
• W2896681144 cites W2071177576 @default.
• W2896681144 cites W2076420181 @default.
• W2896681144 cites W2093635022 @default.
• W2896681144 cites W2094974164 @default.
• W2896681144 cites W2100122945 @default.
• W2896681144 cites W2115919377 @default.
• W2896681144 cites W2127069469 @default.
• W2896681144 cites W2134355588 @default.
• W2896681144 cites W2137321682 @default.
• W2896681144 cites W2147357250 @default.
• W2896681144 cites W2152245709 @default.
• W2896681144 cites W2154659140 @default.
• W2896681144 cites W2162166621 @default.
• W2896681144 cites W2164309162 @default.
• W2896681144 cites W2295774726 @default.
• W2896681144 cites W2346701385 @default.
• W2896681144 cites W2465864705 @default.
• W2896681144 cites W2473943912 @default.
• W2896681144 cites W2585435697 @default.
• W2896681144 doi "https://doi.org/10.1007/s13365-018-0680-y" @default.
• W2896681144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6416234" @default.
• W2896681144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30298202" @default.
• W2896681144 hasPublicationYear "2018" @default.
• W2896681144 type Work @default.
• W2896681144 sameAs 2896681144 @default.
• W2896681144 citedByCount "1" @default.
• W2896681144 countsByYear W28966811442020 @default.
• W2896681144 crossrefType "journal-article" @default.
• W2896681144 hasAuthorship W2896681144A5021428464 @default.
• W2896681144 hasAuthorship W2896681144A5055996321 @default.
• W2896681144 hasAuthorship W2896681144A5060710888 @default.
• W2896681144 hasAuthorship W2896681144A5064879007 @default.
• W2896681144 hasAuthorship W2896681144A5069581471 @default.
• W2896681144 hasAuthorship W2896681144A5076360870 @default.
• W2896681144 hasAuthorship W2896681144A5079973774 @default.
• W2896681144 hasBestOaLocation W28966811441 @default.
• W2896681144 hasConcept C118552586 @default.
• W2896681144 hasConcept C126322002 @default.
• W2896681144 hasConcept C142462285 @default.
• W2896681144 hasConcept C169900460 @default.
• W2896681144 hasConcept C172467417 @default.
• W2896681144 hasConcept C203014093 @default.
• W2896681144 hasConcept C2522874641 @default.
• W2896681144 hasConcept C2777869810 @default.
• W2896681144 hasConcept C2778414717 @default.
• W2896681144 hasConcept C2779298103 @default.
• W2896681144 hasConcept C2779465607 @default.
• W2896681144 hasConcept C2779778239 @default.
• W2896681144 hasConcept C2780593183 @default.
• W2896681144 hasConcept C2781432083 @default.
• W2896681144 hasConcept C2908647359 @default.
• W2896681144 hasConcept C2993143319 @default.
• W2896681144 hasConcept C3013748606 @default.
• W2896681144 hasConcept C70410870 @default.
• W2896681144 hasConcept C71924100 @default.
• W2896681144 hasConcept C99454951 @default.
• W2896681144 hasConceptScore W2896681144C118552586 @default.
• W2896681144 hasConceptScore W2896681144C126322002 @default.
• W2896681144 hasConceptScore W2896681144C142462285 @default.
• W2896681144 hasConceptScore W2896681144C169900460 @default.
• W2896681144 hasConceptScore W2896681144C172467417 @default.
• W2896681144 hasConceptScore W2896681144C203014093 @default.
• W2896681144 hasConceptScore W2896681144C2522874641 @default.
• W2896681144 hasConceptScore W2896681144C2777869810 @default.
• W2896681144 hasConceptScore W2896681144C2778414717 @default.
• W2896681144 hasConceptScore W2896681144C2779298103 @default.
• W2896681144 hasConceptScore W2896681144C2779465607 @default.
• W2896681144 hasConceptScore W2896681144C2779778239 @default.
• W2896681144 hasConceptScore W2896681144C2780593183 @default.

• next